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Abstract 
Aims: EchoCRT was a randomized trial of cardiac resynchronization therapy (CRT) in severely 
symptomatic heart failure (HF) patients with narrow QRS width < 130ms, ejection fraction (EF) 
< 35% and echocardiographic dyssynchrony.  All received CRT implants which were then 
randomized to CRT-On or CRT-Off. While the trial showed no benefit of CRT to these patients, 
the aim of this subgroup analysis was to test the hypothesis that persistent or worsening 
dyssynchrony is associated with unfavorable clinical outcomes. 
Methods and Results: We studied 614 EchoCRT patients with baseline and 6 month 
echocardiograms. Baseline dyssynchrony required for study inclusion was either tissue Doppler 
imaging longitudinal velocity delay > 80 ms, or speckle tracking radial strain delay > 130 ms. 
Persistent dyssynchrony at 6 months was observed similarly in both groups (77% in CRT-On; 
76% in CRT-Off). Persistent dyssynchrony was associated with a significantly higher primary 
end-point of death or HF hospitalization, (HR=1.54, 95% CI 1.03-2.30, p=0.03), and in particular 
secondary endpoint of HF hospitalization (HR=1.66, 95% CI 1.07-2.57, p=0.02). HF 
hospitalizations were also associated with worsening longitudinal dyssynchrony (HR=1.45, 95% 
CI 1.02-2.05, p=0.037), and worsening radial dyssynchrony (HR=1.81, 95% CI 1.16-2.81, 
p=0.008).  Associations of persistent or worsening dyssynchrony with outcomes were similar in 
CRT-Off and CRT-On groups. 
Conclusions:  Persistent or worsening echocardiographic dyssynchrony in HF patients with 
narrow QRS width was a marker for unfavorable clinical outcomes unaffected by CRT.  In 
particular, echocardiographic dyssynchrony on follow-up was strongly associated with HF 
hospitalizations and appears to be a prognostic marker of disease severity. 
Key Words: Heart failure, echocardiography, cardiac resynchronization therapy 
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Introduction 
Cardiac resynchronization therapy (CRT) has been an important advance in the treatment of 
heart failure (HF) patients with reduced left ventricular (LV) ejection fraction (EF) and QRS 
widening.1-3  Many studies have demonstrated that HF patients with widened QRS who have 
measureable differences in timing of regional LV contraction, known as mechanical 
dyssynchrony, have a more favorable response to CRT than those without dyssynchrony.4-9  
Mechanical dyssynchrony is also commonly observed in HF patients with reduced LVEF 
without QRS widening.10-13  EchoCRT tested the hypothesis that CRT may benefit HF patients 
with narrow QRS width (<130ms) and echocardiographic dyssynchrony in a large multicenter 
randomized controlled clinical trial.14  Patients qualified for EchoCRT with New York Heart 
Association (NYHA) Class III or ambulatory Class IV HF with LVEF < 35%, increased LV end-
diastolic diameter (LVEDD) > 55 mm, and dyssynchrony by either tissue Doppler imaging (TDI) 
longitudinal velocity or speckle tracking radial strain before randomization. The main trial 
randomized 809 patients from 115 centers.  EchoCRT was prematurely terminated due to futility 
in affecting the primary combined end-point of death or HF hospitalization and for an observed 
increased mortality in patients with CRT-On.  EchoCRT concluded that CRT does not benefit 
HF patients with mechanical dyssynchrony without QRS widening. 
     Physiological studies have shown that mechanical dyssynchrony impairs LV ejection 
efficiency.15-17 However, the prognostic significance of mechanical dyssynchrony in HF patients 
with narrow QRS width and reduced LVEF remains unclear.  Furthermore, dyssynchrony has 
been observed to change overtime and may relate to the underlying disease process.18 
Accordingly, the aim of this EchoCRT substudy analysis was to test the hypothesis that 
persistent or worsening echocardiographic dyssynchrony is associated with unfavorable clinical 
outcomes, in comparison to HF patients who improve dyssynchrony over time.  A second aim 
was to test for the potential for an interaction of CRT treatment on persistent or worsening 
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dyssynchrony and clinical outcomes. This EchoCRT subgroup consisted of patients with follow-
up echocardiograms for dyssynchrony analysis at 6 months after randomization. 
Methods 
Patient Selection 
The study was compliant with institutional review board or ethics panel review and all patients 
provided written informed consent. All patients were 18 years of age or older, with NYHA class 
III or IV HF on stable medical therapy; QRS duration  < 130 ms; a LVEDD > 55 mm a standard 
indication for an implantable cardioverter–defibrillator (ICD) and echocardiographic evidence of 
LV dyssynchrony. Dyssynchrony was defined by means of color-coded TDI as an opposing-wall 
delay in the peak systolic velocity of >80 ms in apical 4 chamber or apical long-axis views 5, 7or 
by means of speckle-tracking radial strain as a delay in the anteroseptal-to-posterior wall of > 
130 ms or more in the mid-LV short-axis view.19  Patients were excluded with acute 
decompensated HF, intravenous inotropic therapy, atrial fibrillation within the previous month, 
or bradycardia requiring pacing. Patients were implanted with a CRT and defibrillator (CRT-D) 
(Biotronik Lumax, Berlin, Germany) with LV leads placed through epicardial coronary veins 
targeting the posterior or lateral free wall. Patients with successful CRT-D implantation were 
equally randomized to CRT-On or CRT-Off groups. The cohort for the present study consisted 
of 614 patients who had echocardiography at baseline and at 6 months follow-up after 
randomization.  The flow chart (Figure 1) shows the details of patients included in this substudy. 
Echocardiographic Dyssynchrony Analysis 
Quantitative echocardiographic analysis was performed using identical methods at baseline and 
at 6 month follow-up at the University of Pittsburgh echo core lab by investigators blinded to 
randomization and all other clinical data. All sites had formal training classes requiring 
certification of site individuals for image acquisition and analysis, and screening analysis was 
performed by on-site investigators, with confirmatory qualifying analysis performed by the core 
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lab.14 Acquisition used a uniform ultrasound system vendor (GE Vivid 7 or E9, Horton, Norway) 
and analysis software (GE EchoPAC version BT08-09, Horton, Norway).  Off-line dyssynchrony 
analysis by TDI was applied to apical 4 chamber and apical long axis views using color coding 
of the time to peak velocity (tissue synchronization imaging)5 and high frame rates (> 100Hz). 
(Figure 2) Two 7 x 15 mm regions of interest were applied to septal and opposing walls of 4-
chamber and apical long axis views in basal and mid segments.20  The maximal time difference 
in peak longitudinal velocity from opposing walls between aortic valve opening and aortic valve 
closure was averaged from of 3 or more beats.  Dyssynchrony by speckle tracking radial strain 
was assessed from the mid-LV short axis views at frame rates 60-90 Hz. Regions of interest were 
manually drawn on the endocardial and epicardial borders.  The regions of interest were 
manually adjusted to optimize the timing of peak septal thickening (in either anteroseptal or 
septal segments) and posterior wall segments and averaged from 3 or more beats.  Either a TDI 
opposing wall longitudinal velocity delay > 80 ms or a speckle tracking radial strain septal to 
posterior wall delay > 130 ms was required for qualification for EchoCRT.   
Change in Dyssynchrony from Baseline to 6 Month Follow-Up 
The same pre-defined criteria for significant dyssynchrony at baseline above were used at 6 
months. Criteria for worsening dyssynchrony were derived post hoc. Worsening dyssynchrony at 
6 months by TDI longitudinal septal to lateral wall delay as an increase by > 30 ms 
(approximately 40% greater than the baseline entry criterion of 80 ms). Worsening dyssynchrony 
at 6 months by radial strain septal to posterior wall delay by defined as an increase by > 60ms 
(approximately 50% greater than the baseline entry criterion of 130ms).  A 10% greater increase 
in radial strain delay than in TDI velocity delay was chosen to indicate worsening dyssynchrony 
to account for the higher variability in speckle tracking radial strain.  
Echocardiographic Dyssynchrony Variability Analysis 
The inter-observer variability of physicians in the core laboratory in a sample of 50 randomly 
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selected EchoCRT echocardiograms as previously reported had agreement for dyssynchrony as 
follows: TDI opposing wall delay apical 4-chamber view 96% (kappa coefficient 0.92), TDI 
opposing wall delay apical long-axis view 92% (kappa coefficient 0.84), and speckle tracking 
radial strain septal to posterior wall delay 90% (kappa coefficient 0.79), as previously reported.14  
Patient Outcomes  
The primary outcome for EchoCRT was the combined endpoint of all-cause mortality or first 
hospitalization for worsening HF. Secondary outcomes analyzed in this present substudy were 
HF hospitalization alone and all-cause mortality alone. Hospitalization for worsening HF was 
defined as a hospitalization for administration or augmentation of intravenous or oral HF 
therapy, including inotropes, diuretics, and/or vasodilators. Hospitalization was defined as a non-
elective admission of at least one overnight stay. Therapeutic, non-elective interventional 
procedures were considered hospitalizations (such as percutaneous coronary interventions and 
cardiac surgery).  Time to first event was counted from the time of randomization for the 
duration of the study. Follow-up was until the time the study was terminated. 
Statistics 
The study results were analyzed at the independent Statistical Centre at the Robertson Centre for 
Biostatistics, University of Glasgow. Baseline characteristics were reported as means and 
standard deviations for continuous variables (except BNP/NT-proBNP where medians and lower 
and upper quartiles were reported) and counts and percentages for categorical variables and 
treatment group comparisons were based on two-sample t-test (or Mann-Whitney test) and chi-
square (or Fisher’s exact) tests as appropriate.   Hazard ratios and 95% confidence intervals were 
calculated from Cox proportional hazards models including treatment group as a covariate. 
Follow-up was censored at study closure, date of death, LV assist device implantation, heart 
transplant or withdrawal from the study or loss to follow-up whichever came first. Interactions 
between treatment effects and dyssynchrony subgroups were tested for in Cox models that 
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included treatment and dyssynchrony subgroup main effects and interaction terms.  Time-to-
event curves were estimated using the method of Kaplan and Meier.   
Results 
Echocardiographic Dyssynchrony at 6 Months 
The EchoCRT trail was terminated early after interim analysis because of futility in reaching the 
primary endpoint and an observed increase in mortality in the CRT-On group. There were 614 
patients with 6 month follow-up echocardiograms included in this substudy analysis.  Their 
baseline dyssynchrony by randomization was similar as follows: TDI opposing wall delay (4 
Chamber view) 89.1 ±  33.6 ms in CRT-On and 89.4 ± 38.9 ms for CRT-Off,  
TDI opposing wall delay (apical long axis view) 90.1 ± 36.3 for CRT-On and 87.7 ± 41.2 ms,  
Speckle tracking radial strain 217.1 ± 95.4 ms for CRT-On and 223.4 ± 101.7 ms for CRT-Off. 
Their baseline characteristics grouped by presence or absence of significant dyssynchrony on the 
6 month follow-up echocardiogram appears in Table 1. All baseline clinical characteristics were 
similar in both groups except for a greater LVEDD in patients with persistent dyssynchrony 
(66.9 ±7.70 mm versus 65.3±6.98 mm, p=0.02). Baseline characteristics with p<0.1 by 
comparison of groups were LVEF (27.2± 5.42% versus 28.2±5.40 %, p=0.51) and QRS width 
106.3± 12.1 ms versus 104.4± 12.9 ms, p=0.91).  The proportion of patients randomized to CRT-
On versus CRT-OFF had similar significant dyssynchrony at 6 months as follows:, 61% with 
CRT-On and 60 % with CRT-Off had persistent dyssynchrony by TDI in any view (> 80ms), 
45% with CRT-On and 51 % with CRT-Off had persistent dyssynchrony by radial strain (> 
130ms), and 76% with CRT-On and 77 % with CRT-Off had persistent dyssynchrony by either 
TDI or radial strain (Figure 3).  In other words, overall 24% had resolution at 6 months of their 
significant baseline echocardiographic dyssynchrony required for study enrollment, regardless of 
being in CRT-On or CRT-Off groups.   
Associations of Echocardiographic Dyssynchrony at 6 Months with Clinical Outcomes 
8 
 
The mean follow-up period was 19.4 months for all patients and 19.8 months for surviving 
patients.  In this study cohort of 614 patients, 234 patients reached an end-point: 146 HF 
hospitalizations and 88 deaths.  The CRT-On subgroup had 76 HF hospitalizations and 29 deaths 
and the CRT-Off subgroup had 70 HF hospitalizations and 18 deaths. This comparatively greater 
mortality in the CRT-On group is similar to as reported previously in EchoCRT.14  At 6 months, 
there were 469 patients (76%) with persistent dyssynchrony by either TDI longitudinal velocity 
(> 80 ms) or speckle tracking radial strain (> 130ms) and 145 patients (24%) with improvement 
in baseline dyssynchrony with neither significant longitudinal nor radial dyssynchrony at 6 
months. There was a significant association of persistent dyssynchrony with the primary 
outcome of HF hospitalization or death (HR= 1.54, 95% CI 1.03-2.30), p=0.034, Figure 4), and 
in particular with the secondary outcome of HF hospitalization alone (HR= 1.66, 95% CI 1.07-
2.57, p=0.023). Persistent dyssynchrony was not associated with total mortality (p=0.38 
HR=0.75, 95% CI 0.39-1.42).  Regarding CRT-On versus CRT-Off subgroups, there were no 
significant interaction of treatment subgroup with dyssynchrony for the primary endpoint (p = 
0.14) (Figure 5).  
Association of Dyssynchrony at 6 Months with Heart Failure Hospitalization after 
Adjustment for Baseline Characteristics  
We examined 24 baseline characteristics potentially associated with patient outcomes (Table 1). 
Patients were balanced with only 3 variables identified as potentially co-varying with 6 month 
echocardiographic dyssynchrony (p<0.10): LVEDD, LVEF and QRS width.  After statistical 
adjustment for these, persistent dyssynchrony at 6 months remained significantly associated with 
HF hospitalization, HR= 1.57, (95% CI 1.01-2.44), p=0.045. After examining further, there was 
no impact of randomization groups of CRT-On versus CRT-Off and results were similar. There 
was also a trend toward persistent dyssynchrony to be associated with the combined end-point of 
HF hospitalization and death in the model further adjusted for LVEDD, LVEF, QRS width and 
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CRT treatment randomization, p=0.06, HR= 1.47, (95% CI 0.98-2.20).    
Association of Longitudinal and Radial Dyssynchrony at 6 Months with Clinical Outcomes 
Associations of clinical outcomes with longitudinal and radial dyssynchrony individually were 
then determined. There were 608 of 614 total patients (99%) overall with 6 month TDI data 
available. There was a significant association of persistent longitudinal dyssynchrony with HF 
hospitalization, HR= 1.49, (95% CI 1.05-2.12), p=0.027. (Figure 6A).  For the primary end-point 
of total mortality or HF hospitalization, there was a trend toward an association of persistent 
longitudinal dyssynchrony, HR= 1.37, (95% CI 0.99 – 1.90), p=0.061, HR=1.37, (95% CI 0.99-
1.90).  There was no significant association of persistent longitudinal dyssynchrony with total 
mortality, p=0.31, HR=0.74, (95% CI=0.41-1.32).  There was no evidence of an interaction 
between CRT-On and CRT-Off status and association between persistent longitudinal 
dyssynchrony at 6 months and the outcomes of HF hospitalization or death, p = 0.67), HF 
hospitalization alone (p = 0.64) or mortality alone (p = 0.58).  
     There were 536 of 614 total patients (87%) overall with 6 month speckle tracking radial strain 
data available. There was a significant association of persistent radial dyssynchrony with the 
primary outcome of HF hospitalization or death with a HR= 1.43, (95% CI 1.03 - 1.99), p=0.032. 
There was also a significant association of persistent radial dyssynchrony of the secondary 
outcome variable of HF hospitalization alone HR= 1.53, (95% CI 1.08-2.18), p=0.018.  (Figure 
6B).  There was no significant association of persistent radial dyssynchrony with total mortality, 
p=0.62, HR=1.15, (95%CI 0.62-2.13).  There was no evidence of an interaction between CRT-
On and CRT-Off status and the association between  CRT treatment and the primary outcome of 
HF hospitalization or death (p = 0.41), HF hospitalization alone (p = 0.68) or mortality alone (p 
= 0.37).  
Association of Worsening Dyssynchrony at 6 months with Clinical Outcomes 
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There were 155 of 608 patients (25%) with increasing dyssynchrony by TDI longitudinal 
velocity from baseline to 6 months (increasing > 30ms). There was a significant association of 
worsening longitudinal dyssynchrony with the primary outcome of HF hospitalization or death 
with a HR= 1.42, (95% CI 1.02 – 1.97), p=0.037.  There was also a significant association of 
worsening longitudinal dyssynchrony with HF hospitalization, HR = 1.46, 95%CI 1.03-2.06, 
p=0.034. (Figure 7A).  Worsening longitudinal dyssynchrony was not associated with mortality, 
p=0.788. These results appeared unaffected by CRT with no interaction observed between 
randomization treatment (CRT-On vs. CRT-Off) and these clinical end-points (p = 0.128 and p = 
0.340). There were 64 of 507 patients (13%) with worsening dyssynchrony by radial strain from 
baseline to 6 months (increasing > 60ms). There was a significant association of worsening 
radial dyssynchrony with the primary outcome of HF hospitalization or death with a HR= 1.62, 
(95% CI 1.06 – 2.49), p=0.027.  There was also a highly significant association of worsening 
radial dyssynchrony with HF hospitalization with a HR = 1.81, 95% CI 1.16-2.81, p=0.008. 
(Figure 7B).  Once again, there was no association of worsening dyssynchrony with mortality, 
p=0.899 and no interaction observed between randomization treatment and clinical end-points.  
Discussion 
This substudy of the EchoCRT randomized clinical trial of HF patients with narrow QRS width 
demonstrated that persistent or worsening echocardiographic dyssynchrony from baseline to 6 
month follow-up was associated with unfavorable clinical outcomes, in particular HF 
hospitalizations.  The post hoc observation that dyssynchrony on follow-up echocardiography 
was associated with patient outcome was similar in both randomization groups, and thus 
appeared unaffected by CRT.  This study did not provide mechanistic evidence and these 
observations may be considered hypothesis generating. EchoCRT enrolled HF patients with 
relatively narrow QRS duration (<130ms), LV dilatation, reduced LVEF, and baseline 
echocardiographic dyssynchrony, and concluded that CRT was not of benefit.14  All patients 
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required baseline echocardiographic dyssynchrony for entry into the trial. Of interest, 76% were 
observed to have persistent dyssynchrony at 6 months and 24% improved to having no 
significant dyssynchrony at follow-up. Improvement in dyssynchrony was similar in CRT-On 
and CRT-Off groups, and no interaction with treatment randomization was demonstrated.  
Importantly, persistent dyssynchrony at 6 months was significantly associated with the primary 
outcome variable of HF hospitalization or death and HF hospitalization alone.  Even after 
adjusting for the potential confounding variables, persistent dyssynchrony remained significantly 
associated with HF hospitalization.  As further evidence to support this association, both TDI 
longitudinal dyssynchrony and speckle tracking radial strain dyssynchrony at 6 months when 
examined separately were significantly associated with HF hospitalization, which was also 
unaffected by CRT randomization. Furthermore, increases in either TDI longitudinal or speckle 
tracking radial dyssynchrony from baseline to 6 months were significantly associated with both 
the primary outcome variable and in particular HF hospitalization alone. These consistent 
observations support echocardiographic dyssynchrony as potentially a new prognostic marker in 
HF patients with reduced LVEF and narrow QRS width, in particular for HF hospitalizations. 
Since these associations were similar in CRT-On and CRT-Off groups, our results suggest that 
echocardiographic dyssynchrony may possibly be a marker for unfavorable LV mechanics and 
more severe myocardial disease in patients with narrow QRS width.  
     Many previous investigations have focused on baseline echocardiographic dyssynchrony in 
HF patients with QRS widening before CRT as a marker for a more favorable response to CRT.4-
9, 19, 21, 22  Several other studies in HF patients with QRS widening have reported dyssynchrony 
after CRT as a marker for unfavorable outcomes.  Bleeker et al. demonstrated lack of 
improvement in TDI longitudinal velocity opposing wall delay assessed immediately after CRT 
was associated with lack of LV reverse remodeling at 6 months. 23 Auger et al. also reported the 
association of worsening dyssynchrony by TDI velocity after CRT with less LV reverse 
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remodeling and worse survival.24 Saba et al. using an echo-guided LV lead placement strategy, 
demonstrated that patients who did not improve radial strain dyssynchrony had higher rates of 
death or HF hospitalization after CRT.25 Stankovic et al. also showed that lack of improvement 
of dyssynchrony assessed by apical rocking was associated with less favorable clinical outcomes 
after CRT. 26 Furthermore, Doltra et al. recently showed that lack of improvements in septal 
flash, abnormal ventricular filling, or exaggerated interventricular dependence after CRT were 
associated with less LV reverse remodeling and patient survival. 27  Echocardiographic 
dyssynchrony after CRT in HF patients with QRS widening is also a marker for ventricular 
arrhythmias. 28 29  Interesting, patients with severe HF and worsening dyssynchrony after CRT 
were shown to be at the greatest risk for serious ventricular arrhythmias. 29  
     There is much less reported on the significance of dyssynchrony in HF patients with narrow 
QRS duration unrelated to CRT.  Mechanical dyssynchrony may likely represent different 
pathophysiological phenomena in patients with widened versus narrow QRS durations.30  
Yamada et al. also reported mechanical dyssynchrony to precede widening of the QRS complex 
as a marker for progression of myocardial disease in knockout murine surrogate of human 
cardiomyopathy.31 Tanaka et al. studied dyssynchrony in 201 HF patients with narrow QRS and 
acute non-ischemic cardiomyopathy. They observed dyssynchrony to be present in 54% at HF 
presentation which decreased to 12% at 6 month follow-up when treated with routine medical 
therapy.18 Improvements in LV dyssynchrony and cardiac function in non-ischemic disease were 
perhaps related to changes in myocardial inflammation which may have heterogeneous effects on 
regional contractility.18  Recent work has demonstrated that pattern of dyssynchrony by strain 
imaging might be more important than a delay in time-to-peak between segments in 
differentiating the electromechanical substrate that is responsive to CRT from pure mechanical 
delay resulting from regional contraction heterogeneity or scar that is unresponsive to CRT. 
Myocardial ischemic, infarction and scar represent other pathophysiologic basis for LV 
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dyssynchrony in patients with narrow QRS width. 32 Accordingly, LV dyssynchrony may 
originate from different myocardial substrates, including an electromechanical substrate regional 
contraction delays from delayed electrical activation, and non-electrical dyssynchrony substrates, 
such as contraction heterogeneity or scar.16  The basis for improvements in LV dyssynchrony 
observed in the present substudy of HF patients with narrow QRS, including improvements in 
the control group is unknown.  We may hypothesize that changes in LV dyssynchrony may have 
related to yet undefined factors affecting regional contractility or result from effects of medical 
therapy on LV reverse remodeling.  Overall, EchoCRT patients received intensive medical 
therapy of agents with known effects on reverse remodeling; 95% were on an angiotensin 
converting enzyme inhibitor or an aldersterone receptor blocker and 97% were on beta-blocker 
therapy. Further investigation of factors influencing LV mechanical dyssynchrony in HF is 
warranted. 
Limitations 
It is a limitation that this study was confined to patients in the EchoCRT trial who had 6 month 
echocardiograms available for analysis. Since the study was terminated prematurely, several 
patients did not have 6 month echocardiograms performed.  It is a limitation that dyssynchrony 
measures are limited to baseline and 6 month time points, so we are unable to exclude possible 
changes in dyssynchrony that may have occurred in the interim. A limitation was that 
dyssynchrony analysis was limited to peak-to-peak timing and further analysis of velocity or 
strain was not part of this present study. Another limitation is that speckle tracking 
echocardiography could not be performed on all patients and was available on 87%, similar to 
the yield on previous studies.6, 19 TDI data were available on 99% of patients. The advantage of 
speckle tracking strain over TDI velocity is that strain is less affected by passive motion or 
tethering, such as occurs in scar. It is a major limitation that scar as a source of dyssynchrony 
was not assessed by an alternate imaging technique, such as contrast cardiac magnetic resonance 
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imaging. It was a limitation that the definitions we used for worsening dyssynchrony were 
determined post hoc and there are no previous published criteria for worsening dyssynchrony in 
this unique population. Our major results were reported on persistent dyssynchrony using pre-
defined criteria and findings on worsening dyssynchrony should be considered as supplemental. 
Future prospective study of criteria for worsening dyssynchrony is warranted. Another limitation 
was that the relationship of LV lead position to patient outcome was not part of the present study, 
but the associations of persistent or worsening dyssynchrony with clinical outcomes were similar 
in CRT-On and CRT-Off groups.25 A significant limitation in previous studies has been 
variability of dyssynchrony measures.33 This study limited variability by using a single 
ultrasound vendor and analysis software and a core echocardiography laboratory with 
documented favorable reproducibility.  However, the interplay of variabilities in complex 
measurements including differences between measurements taken at baseline and 6 months are 
not clearly defined and remains a limitation. 
Conclusions 
Persistent or worsening echocardiographic dyssynchrony in HF patients with narrow QRS width 
and reduced LVEF at 6 month follow-up was associated with the combined end-point of HF 
hospitalizations or death and in particular HF hospitalizations alone, regardless of CRT-On or 
CRT-Off. Accordingly, improvement in dyssynchrony was associated with less HF 
hospitalizations or deaths. Persistent or worsening echocardiographic dyssynchrony appears to 
be a marker for disease severity in HF patients and has prognostic significance.  The relative 
value of persistent dyssynchrony in comparison to established markers of HF prognosis are 
unknown and further prospective multivariable study is warranted.  
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Figure Legends 
Figure 1. Flow chart of patients included in this subgroup analysis from all patients randomized 
in the EchoCRT trial. 
Figure 2.  Representative echocardiographic examples of study patients with (A) persistent 
dyssynchrony and (B) improved dyssynchrony at 6 months. At Baseline, Patient A had tissue 
Doppler longitudinal peak velocity delay (arrows) of 140 ms within the ejection interval (top row 
left) and speckle tracking radial strain septal (yellow line) to posterior wall (purple line) delay 
(arrows) of 197ms (2nd row left). At 6 month follow-up Patient A had persistent longitudinal 
velocity delay (arrows) of 150ms (top row right) and radial strain delay (arrows) of 184ms (2nd 
row right). At Baseline, Patient B had longitudinal velocity delay (arrows) of 139 ms (3rd row 
left) and radial strain delay (arrows) of 165ms (bottom row left). At 6 month follow-up, Patient B 
had improvement in longitudinal velocity delay (arrows) to 14 ms (3rd row right) and radial strain 
delay (arrows) to 27 ms (bottom row right). AVO= aortic valve opening, AVC = aortic valve 
closure. 
Figure 3. Bar graphs of frequency of echocardiographic dyssynchrony at 6 months after 
randomization in the EchoCRT trial. TDI = tissue Doppler imaging. 
Figure 4.  Kaplan-Meier plots of all patients demonstrating the significant association of 
echocardiographic dyssynchrony at 6 months with the primary outcome variable of death or 
hospitalization for heart failure. mo. = months 
Figure 5.  Kaplan-Meier plots of subgroups divided by randomization to cardiac 
resynchronization therapy (CRT) on or off and echocardiographic dyssynchrony at 6 months.  
There was no significant interaction observed with CRT and echocardiographic dyssynchrony on 
the primary outcome or other outcome variables. Dys. = dyssynchrony, mo. = months 
20 
 
Figure 6. Kaplan-Meier plots demonstrating the significant association echocardiographic 
dyssynchrony at 6 months by (A) longitudinal velocity or (B) radial strain with heart failure 
hospitalization in all patients. Dys = dyssynchrony, mo. = months. 
Figure 7. Kaplan-Meier plots demonstrating the significant association of worsening 
echocardiographic dyssynchrony at 6 months by (A) longitudinal velocity or (B) radial strain 
with heart failure hospitalization in all patients. mo. = months. 
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Table 1: Baseline characteristics of all 614 patients grouped by presence or 
absence of echocardiographic dyssynchrony at 6 month follow-up.  
 
 Patients without 
Dyssynchrony at 6 mo. 
(n=145) 
Patients with 
Dyssynchrony at 6 mo. 
(n=469) 
 
P 
Age (years)  58.6 (11.81)  58.1 (12.78)  0.686 
Male Sex 111 (76.55%)  334 (71.22%)  0.209 
QRS width (ms) 104.4 (12.90)  106.3 (12.08)  0.091 
Walking distance (m)  327.0 (124.11)  330.6 (115.32)  0.744 
Quality of life score  52.3 (24.41)  50.3 (24.15)  0.400 
NYHA Class (II, III, IV) 2.07%, 95.17%, 2.76% 3.20%, 93.39%, 2.56%   
BNP (pg/ml)  265.5 (92.00) 224.0 ( 97.50)  0.653 
NT-proBNP (pg/ml)  984.0 (402.00)  1154.0 (465.50)  0.643 
Systolic Blood Pressure (mmHg)  119.3 (21.56)  119.7 (18.62)  0.821 
Diastolic Blood Pressure (mmHg)  73.2 (13.30)  72.9 (11.43)  0.742 
Body mass index (kg/m2)  30.4 (7.42)  31.2 (13.32)  0.532 
Ischemic disease  77 (53.10%)  254 (54.27%)  0.805 
Hypertension  98 (68.53%)  306 (65.52%)  0.506 
Prior stroke or TIA  14 (9.72%)  50 (10.75%)  0.725 
Diabetes  50 (34.48%)  181 (38.68%)  0.363 
Chronic lung disease  27 (18.75%)  90 (19.31%)  0.881 
Chronic kidney disease  21 (14.58%)  63 (13.49%)  0.739 
LVEF Biplane (%)  28.2 (5.40)  27.2 (5.42)  0.051 
LV end diastolic diameter (mm)  65.3 (6.98)  66.9 (7.70)  0.020 
Dyssynchrony Qualification:   0.215 
    TDI only  33 (22.76%)  112 (23.93%)   
  
 
    Radial strain only 39 (26.90%)  94 (20.09%)  
    Both TDI and radial strain 73 (50.34%)  262 (55.98%) 
ACE inhibitor or ARB  139 (95.86%)  446 (95.10%)  0.704 
Aldosterone antagonist  83 (57.24%)  272 (58.00%)  0.872 
Beta-blocker  141 (97.24%)  454 (96.80%)  1.000 
Diuretic agent  121 (83.45%)  409 (87.21%)  0.250 
NYHA = New York Heart Association, BNP = brain naturetic peptide, TIA = transient ischemic 
attack, LV = left ventricular, EF=ejection fraction, TDI = tissue Doppler imaging, ACE = 
angiotensin converting enzyme, ARB = angiotensin II receptor blockers, mo = months 
 
 
